呼吸

订阅

MedSci主页 / 所有栏目 / 呼吸

非控制性哮喘治疗的CD6靶向抗体Itolizumab的Ib期临床试验正式开始

2019-07-11 Allan MedSci原创

ItolizumabCD6非控制性哮喘
关注

Equillium是一家生物技术公司，近日CD6靶向抗体Itolizumab的Ib期临床试验（EQUIP）已正式开始，用于治疗不受控制的中度至重度哮喘患者。

Equillium是一家生物技术公司，近日CD6靶向抗体Itolizumab的Ib期临床试验（EQUIP）已正式开始，用于治疗不受控制的中度至重度哮喘患者。

EQUIP Ib期研究的首席研究员，皇家墨尔本医院Jo Douglass教授说：“尽管目前的标准疗法，包括支气管扩张剂和吸入皮质类固醇，能够控制患者症状，但在某些情况下许多患者仍然会出现症状。对于这种疾病的生物学复杂性，仍需要具有独特作用机制的新型靶向治疗方法，即无论嗜酸性粒细胞水平如何，药物都能在各种类型的哮喘中发挥作用。Itolizumab能够抑制不同效应T细胞亚型（包括Th2和Th17），而这些亚型在哮喘的发病机制中起重要作用”。


原始出处：

http://www.firstwordpharma.com/node/1652278#axzz5tMRLVCBr

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1912174, encodeId=ffa519121e46a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jul 21 22:42:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940334, encodeId=c14a1940334e7, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Thu Sep 05 16:42:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058319, encodeId=f760205831963, content=<a href='/topic/show?id=e8254354e7' target=_blank style='color:#2F92EE;'>#CD6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4354, encryptionId=e8254354e7, topicName=CD6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Tue Feb 04 12:42:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552242, encodeId=9eef155224223, content=<a href='/topic/show?id=6c0c101142d' target=_blank style='color:#2F92EE;'>#Itolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10114, encryptionId=6c0c101142d, topicName=Itolizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0bb14274401, createdName=李研东, createdTime=Sat Jul 13 09:42:00 CST 2019, time=2019-07-13, status=1, ipAttribution=)]
    2019-07-21 snf701207

    #mAb#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1912174, encodeId=ffa519121e46a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jul 21 22:42:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940334, encodeId=c14a1940334e7, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Thu Sep 05 16:42:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058319, encodeId=f760205831963, content=<a href='/topic/show?id=e8254354e7' target=_blank style='color:#2F92EE;'>#CD6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4354, encryptionId=e8254354e7, topicName=CD6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Tue Feb 04 12:42:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552242, encodeId=9eef155224223, content=<a href='/topic/show?id=6c0c101142d' target=_blank style='color:#2F92EE;'>#Itolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10114, encryptionId=6c0c101142d, topicName=Itolizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0bb14274401, createdName=李研东, createdTime=Sat Jul 13 09:42:00 CST 2019, time=2019-07-13, status=1, ipAttribution=)]
    2019-09-05 bioon3

    #Ib期#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1912174, encodeId=ffa519121e46a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jul 21 22:42:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940334, encodeId=c14a1940334e7, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Thu Sep 05 16:42:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058319, encodeId=f760205831963, content=<a href='/topic/show?id=e8254354e7' target=_blank style='color:#2F92EE;'>#CD6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4354, encryptionId=e8254354e7, topicName=CD6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Tue Feb 04 12:42:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552242, encodeId=9eef155224223, content=<a href='/topic/show?id=6c0c101142d' target=_blank style='color:#2F92EE;'>#Itolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10114, encryptionId=6c0c101142d, topicName=Itolizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0bb14274401, createdName=李研东, createdTime=Sat Jul 13 09:42:00 CST 2019, time=2019-07-13, status=1, ipAttribution=)]
    2020-02-04 amy0550

    #CD6#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1912174, encodeId=ffa519121e46a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jul 21 22:42:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940334, encodeId=c14a1940334e7, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Thu Sep 05 16:42:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058319, encodeId=f760205831963, content=<a href='/topic/show?id=e8254354e7' target=_blank style='color:#2F92EE;'>#CD6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4354, encryptionId=e8254354e7, topicName=CD6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Tue Feb 04 12:42:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552242, encodeId=9eef155224223, content=<a href='/topic/show?id=6c0c101142d' target=_blank style='color:#2F92EE;'>#Itolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10114, encryptionId=6c0c101142d, topicName=Itolizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0bb14274401, createdName=李研东, createdTime=Sat Jul 13 09:42:00 CST 2019, time=2019-07-13, status=1, ipAttribution=)]
    2019-07-13 李研东

    #Itolizumab#

    0